Author:
Ettl J.,Quek R.G.W.,Lee K.-H.,Rugo H.S.,Hurvitz S.,Gonçalves A.,Fehrenbacher L.,Yerushalmi R.,Mina L.A.,Martin M.,Roché H.,Im Y.-H.,Markova D.,Bhattacharyya H.,Hannah A.L.,Eiermann W.,Blum J.L.,Litton J.K.
Reference15 articles.
1. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation;Litton,2017
2. Addition of drug/s to a chemotherapy regimen for metastatic breast cancer;Butters;Cochrane Database Syst Rev,2010
3. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology;Aaronson;J Natl Cancer Inst,1993
4. EORTC QLQ-C30 Scoring Manual;Fayers,2001
5. Interpreting the significance of changes in health-related quality-of-life scores;Osoba;J Clin Oncol,1998
Cited by
108 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献